Alnylam Pharmaceuticals, Inc. (ALNY)

NASDAQ: ALNY · Real-Time Price · USD

475.91

-2.67 (-0.56%)

At close: Oct 28, 2025, 4:00 PM EDT

474.21

-1.70 (-0.36%)

Pre-market: Oct 29, 2025, 4:35 AM EDT

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2011 - 2020
AMVUTTRA Revenue	1.35B	970.45M	Log In	Log In	Log In	Upgrade
ONPATTRO Revenue	208.42M	252.86M	Log In	Log In	Log In	Upgrade
GIVLAARI Revenue	283.51M	255.87M	Log In	Log In	Log In	Upgrade
OXLUMO Revenue	172.75M	167.05M	Log In	Log In	Log In	Upgrade
Total Product Revenue	2.01B	1.65B	Log In	Log In	Log In	Upgrade
Roche - Collaboration Revenue	63.63M	119.49M	Log In	Log In	Log In	Upgrade
Regeneron Pharmaceuticals - Collaboration Revenue	152.19M	302.80M	Log In	Log In	Log In	Upgrade
Novartis AG - Collaboration Revenue	-	79.76M	Log In	Log In	Log In	Upgrade
Vir Biotechnology - Collaboration Revenue	-	-	Log In	Log In	Log In	Upgrade
Other - Collaboration Revenue (Pre-FY2023)	-	-	Log In	Log In	Log In	Upgrade
Other - Collaboration Revenue (Post-FY2022)	46.27M	8.18M	Log In	Log In	Log In	Upgrade
Total Collaboration Revenue	325.02M	510.22M	Log In	Log In	Log In	Upgrade
Royalty Revenue	125.22M	91.79M	Log In	Log In	Log In	Upgrade
Revenue (Other)	-262.08M	-510.22M	Log In	Log In	Log In	Upgrade
Revenue (Total)	2.46B	2.25B	Log In	Log In	Log In	Upgrade

Updated Jul 31, 2025. Data Source: Fiscal.ai.